Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
UFP Technologies, Inc. (UFPT)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$329.82+17.66%
Close 2026-11-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
10.85 → 10.85 EPS · FY ending Dec 31, 2027 · 3 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 3 to 3; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for UFPT yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Expand facilities in the Dominican Republic | The company plans new factories in the Dominican Republic. | Intact | Facilities not operational by end of 2026 | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 3 of 4 supplied quarters. Management reported: ““Operationally, we are seeing meaningful improvements across our businesses, including scaling new programs in the Dominican Republic and margin improvements in our legacy UFP operations.” “However, scheduled program transfers to the Dominican Republic and margin improvement remain behind plan."” Revenue was $173.964 million in 2026-Q2. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
UFPT is a growth-oriented medical technology supplier with a multi-year thesis built on capacity growth and focus on higher-growth medical segments. The thesis is currently intact, with recent financial performance in the top half of its industry and management’s main operating priorities on track. Acquisition progress is mixed, and earnings quality is rated neutral.
The evidence gives mixed valuation signals: UFPT is described as cheap versus peers, while also carrying a near-peer premium and an elevated fragility flag tied to expensive valuation and weak execution quality. The expectations gap is modest, but the evidence does not specify what earnings assumptions the market has already embedded.
Near term, recent results have been strong, with two reported earnings beats and second-quarter revenue up 15.1% year over year; year-to-date sales are up 9.6%. Capacity investment in the Dominican Republic is delivering early operating benefits but also some near-term margin pressure. A guidance cut, weaker jobs data, or continued peer misses could weigh on the business outlook, although the evidence rates near-term miss risk as low.
Over the next one to three years, the thesis depends on capacity expansion translating into sustained growth and improved cost structure, while medical segment strength continues. It also hinges on disciplined acquisition execution and whether sector conditions remain supportive. Guidance changes, employment weakness, and results from healthcare bellwethers are key near-term signals.
UFPT’s long-term thesis is intact, with strong recent performance and progress on core priorities, but valuation and execution concerns limit confidence in how durable that progress will be. The multi-year view hinges on continued growth, successful capacity expansion, and a supportive sector backdrop. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
EPS at or above $2.24 per share | Profit per share is expected above $2.24 next year. | Intact | EPS guidance falls below $2.24 for FY26 | Diluted EPS: $2.68 per share FY2026-Q2; GAAP. Published target: >=2.24 USD per share. Annual target cannot be compared with a quarterly or TTM observation. Aug 6, 20262.68 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Grow revenue in high-growth MedTech segments | A primary condition in UFP Technologies, Inc.'s published investment case. The stated target is >=7.6% YoY revenue growth. | Intact | YoY revenue growth falls below 7.6% in FY26 | Revenue growth: 15.07% FY2026-Q2; GAAP. Published target: >=7.6% YoY revenue growth. Annual target cannot be compared with a quarterly or TTM observation. Aug 6, 202615.073821 percent · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$10.66 → $10.85 · observed estimates
$0.68B → $0.70B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $10.66 | $678,912,725 | 3 / 3 |
| 2026-07-25 | $11.69 | $678,987,750 | 4 / 4 |
| 2026-07-26 | $11.69 | $678,987,750 | 4 / 4 |
| 2026-07-27 | $11.69 | $678,987,750 | 4 / 4 |
| 2026-07-28 | $11.69 | $678,987,750 | 4 / 4 |
| 2026-07-29 | $10.66 | $678,912,725 | 3 / 3 |
| 2026-07-30 | $10.66 | $678,912,725 | 3 / 3 |
| 2026-07-31 | $10.66 | $678,912,725 | 3 / 3 |
| 2026-08-01 | $10.66 | $678,912,725 | 3 / 3 |
| 2026-08-02 | $11.69 | $678,987,750 | 4 / 4 |
| 2026-08-03 | $11.69 | $678,987,750 | 4 / 4 |
| 2026-08-04 | $10.66 | $678,912,725 | 3 / 3 |
| 2026-08-05 | $10.66 | $678,912,725 | 3 / 3 |
| 2026-08-06 | $11.81 | $690,248,750 | 4 / 4 |
| 2026-08-08 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-08-09 | $11.84 | $694,073,750 | 4 / 4 |
| 2026-08-10 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-08-12 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-08-13 | $11.87 | $698,948,750 | 4 / 4 |
| 2026-08-14 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-08-15 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-08-16 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-08-17 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-08-18 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-08-19 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-08-20 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-08-21 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-08-22 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-08-23 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-08-24 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-08-25 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-08-26 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-08-27 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-08-28 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-08-29 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-08-30 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-08-31 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-09-01 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-09-02 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-09-03 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-09-04 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-09-05 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-09-06 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-09-07 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-09-08 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-09-09 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-09-10 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-09-11 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-09-12 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-09-13 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-09-14 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-09-15 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-09-16 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-09-17 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-09-18 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-09-19 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-09-20 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-09-21 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-09-22 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-09-23 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-09-24 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-09-25 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-09-26 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-09-27 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-09-28 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-09-29 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-09-30 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-10-01 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-10-02 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-10-03 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-10-04 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-10-05 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-10-06 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-10-07 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-10-08 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-10-09 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-10-10 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-10-11 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-10-12 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-10-13 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-10-14 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-10-15 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-10-16 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-10-17 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-10-18 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-10-19 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-10-20 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-10-21 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-10-22 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-10-23 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-10-24 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-10-25 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-10-26 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-10-27 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-10-28 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-10-29 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-10-30 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-10-31 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-11-01 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-11-02 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-11-03 | $10.85 | $698,948,825 | 3 / 3 |
| 2026-11-04 | $10.85 | $698,948,825 | 3 / 3 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 2 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.